See more : PagerDuty, Inc. (PD) Income Statement Analysis – Financial Results
Complete financial analysis of Tien Liang BioTech Co., Ltd. (4127.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tien Liang BioTech Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Paragon Finance Limited (PARAGONF.BO) Income Statement Analysis – Financial Results
- Hamilton Insurance Group, Ltd. (HG) Income Statement Analysis – Financial Results
- Silver Range Resources Ltd. (SLRRF) Income Statement Analysis – Financial Results
- Datto Holding Corp. (MSP) Income Statement Analysis – Financial Results
- American Pacific Rim Commerce Group (APRM) Income Statement Analysis – Financial Results
Tien Liang BioTech Co., Ltd. (4127.TWO)
About Tien Liang BioTech Co., Ltd.
Tien Liang BioTech Co., Ltd. manufactures and sells pharmaceutical products in Taiwan and internationally. The company offers Chinese medicine products, such as pills for liver and kidney deficiency, low back pain, sore feet, dizziness, thirst, dry tongue, sore throat, and heel pain, as well as rheumatism, joint pain, traveling pain, wind-cold-dampness, gout, neuralgia, enuresis, hemorrhoids, constipation, athlete's foot, fall injuries, cold, bronchitis, cough, and phlegm indications. It provides western medicine products, including ointment, hair removal cream, tablet, capsule, soreness spray, and pain patch products, as well as pain relief gels. In addition, the company offers healthcare products; and other products for body relaxation and comfort, and relieving discomfort after exercise, as well as tooth products and soaps. The company was founded in 1960 and is based in New Taipei City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 459.99M | 528.52M | 571.32M | 431.08M | 435.86M |
| Cost of Revenue | 173.85M | 191.98M | 233.04M | 179.13M | 194.03M |
| Gross Profit | 286.15M | 336.55M | 338.28M | 251.96M | 241.83M |
| Gross Profit Ratio | 62.21% | 63.68% | 59.21% | 58.45% | 55.48% |
| Research & Development | 1.28M | 1.40M | 1.20M | 1.24M | 991.00K |
| General & Administrative | 45.61M | 46.07M | 45.76M | 49.51M | 0.00 |
| Selling & Marketing | 220.38M | 230.79M | 248.38M | 251.89M | 0.00 |
| SG&A | 266.00M | 276.86M | 294.14M | 301.40M | 284.25M |
| Other Expenses | -1.56M | 2.67M | 7.66M | 4.01M | 0.00 |
| Operating Expenses | 265.71M | 278.26M | 295.33M | 302.64M | 285.25M |
| Cost & Expenses | 439.56M | 470.24M | 528.37M | 481.76M | 479.28M |
| Interest Income | 599.00K | 142.00K | 30.00K | 36.00K | 103.00K |
| Interest Expense | 2.08M | 1.77M | 1.85M | 1.96M | 2.62M |
| Depreciation & Amortization | 10.55M | 11.05M | 12.43M | 14.85M | 17.58M |
| EBITDA | 31.05M | 72.15M | 63.06M | -31.79M | -21.56M |
| EBITDA Ratio | 6.75% | 13.65% | 11.04% | -7.37% | -4.95% |
| Operating Income | 20.44M | 61.10M | 50.63M | -46.63M | -43.42M |
| Operating Income Ratio | 4.44% | 11.56% | 8.86% | -10.82% | -9.96% |
| Total Other Income/Expenses | -2.02M | 1.04M | 5.84M | 2.09M | 1.66M |
| Income Before Tax | 18.42M | 59.33M | 48.78M | -48.59M | -41.76M |
| Income Before Tax Ratio | 4.00% | 11.23% | 8.54% | -11.27% | -9.58% |
| Income Tax Expense | 684.00K | -152.00K | 2.18M | 3.04M | 5.01M |
| Net Income | 17.73M | 59.48M | 46.61M | -51.64M | -46.78M |
| Net Income Ratio | 3.85% | 11.25% | 8.16% | -11.98% | -10.73% |
| EPS | 0.39 | 1.30 | 1.02 | -1.13 | -1.02 |
| EPS Diluted | 0.39 | 1.30 | 1.02 | -1.13 | -1.02 |
| Weighted Avg Shares Out | 45.76M | 45.76M | 45.76M | 45.76M | 45.76M |
| Weighted Avg Shares Out (Dil) | 45.76M | 45.76M | 45.76M | 45.76M | 45.76M |
Source: https://incomestatements.info
Category: Stock Reports